2023
Using dimensionality-reduction techniques to understand the organization of psychotic symptoms in persistent psychotic illness and first episode psychosis
Fleming L, Lemonde A, Benrimoh D, Gold J, Taylor J, Malla A, Joober R, Iyer S, Lepage M, Shah J, Corlett P. Using dimensionality-reduction techniques to understand the organization of psychotic symptoms in persistent psychotic illness and first episode psychosis. Scientific Reports 2023, 13: 4841. PMID: 36964175, PMCID: PMC10039017, DOI: 10.1038/s41598-023-31909-w.Peer-Reviewed Original ResearchConceptsHallucinations/delusionsFirst-episode psychosisFirst-episode psychosis participantsEarly intervention programsPathophysiological mechanismsUnderlying pathophysiologyEpisode psychosisPsychotic illnessPsychotic symptomsPsychotic disordersSchizoaffective disorderAuditory hallucinationsPositive symptomsHallucination severityNegative symptomsSymptomsDisorganization symptomsIntervention programsHallucinationsIllnessPsychosis participantsPsychosisDelusionsDisordersParticipants
2000
Phencyclidine Model of Frontal Cortical Dysfunction in Nonhuman Primates
Jentsch J, Taylor J, Roth R. Phencyclidine Model of Frontal Cortical Dysfunction in Nonhuman Primates. The Neuroscientist 2000, 6: 263-270. DOI: 10.1177/107385840000600409.Peer-Reviewed Original ResearchPrefrontal cortexFrontal cortical dysfunctionPCP-induced behaviorsIdiopathic psychotic disordersPathophysiology of schizophreniaSchizophrenia-like symptomatologyLong-term intakeDopaminergic interactionsCortical dysfunctionNeurochemical dysfunctionNeurochemical effectsReceptor antagonistCognitive dysfunctionPhencyclidine modelPrimary symptomsPsychotic disordersDysfunctionNonhuman primatesNeurobiological substratesHuman subjectsBehavioral changesCortexSchizophreniaDisordersAberrant behavior